Ten private medical technology companies showcase innovation pathways ranging from needle-free glucose monitoring to robotic surgery and early cancer screening

Overview

The report compiles case studies of ten companies featured at Bernstein's inaugural The Makings of Medtech private company conference, covering metabolic monitoring, neuromodulation, orthopedic implants, heart failure interventions, stroke thrombectomy, surgical robotics, robotic bronchoscopy, and in vitro diagnostics. Rather than providing a unified valuation, the report focuses on the clinical gaps addressed by each technology, their differentiated mechanisms, commercialization progress, and the conditions required for the next stage of validation.

Core views

The report first places the ten companies under a common innovation theme: medical technology is transforming diagnostic and treatment workflows through lower invasiveness, more personalized devices, robotics and real-time imaging, and novel blood biomarkers. The companies are at different stages, with some already FDA-cleared and commercialized while others still need to complete pivotal clinical trials or obtain PMA approval. Their opportunities must therefore be understood individually in the context of adoption pathways, manufacturing scale-up, referral networks, regulatory progress, and economics. Biolinq is developing Shine for people with type 2 diabetes who do not use insulin. The product has received FDA De Novo clearance and continuously measures glucose through a shallow intradermal microsensor worn on the forearm while integrating activity and sleep data. Blue, yellow, and red LEDs directly indicate the glucose range, while a mobile application provides more detailed trends. The company believes this large population currently has low penetration because traditional finger-stick testing and conventional continuous glucose monitoring have not sufficiently driven behavioral change. Even using only one sensor per month, quarter, or year could provide more insight than year-round finger-stick testing. Flashing prompts encourage immediate actions such as walking, while the needle-free form factor that does not depend on a phone is also suitable for intermittent wear. The key uncertainty is what product form and information presentation the target population will accept. During scale-up, consistency in sensor chemistry, calibration, assembly, accuracy, and yield will also be important. Biolinq believes its semiconductor manufacturing process can provide tighter process control. Insightec's Exablate platform uses MR-guided focused ultrasound to ablate deep brain tissue without opening the skull and has received FDA approval for drug-refractory essential tremor and certain motor symptoms of Parkinson's disease. The therapy is typically completed in a single outpatient session lasting approximately two hours, and patients generally return home the same day. With the latest Exablate Prime platform, approximately 40% of recent cases have been shortened to 1 hour. Through automation of algorithms, software, and interfaces, some institutions can perform 4 to 5 brain procedures within 8 to 10 hours. The report emphasizes that growth depends not only on the technology but also on building referral networks between neurosurgeons and the neurologists who manage patients. Focused-ultrasound treatment volume grew 4 times during the stated period, while deep brain stimulation grew 1.5 times, indicating that focused ultrasound is primarily unlocking demand from patients who previously did not undergo surgery rather than simply replacing deep brain stimulation. The next opportunity is approximately 1 million U.S. Parkinson's disease patients, but the referral-building experience from the essential tremor market must still be replicated. restor3d combines CT data, AI-assisted planning, digital design, and in-house 3D printing to produce personalized or standardized implants for the shoulder, knee, hip, foot, and ankle. Management believes that conventional off-the-shelf implants use a limited range of sizes for a large patient population, restricting anatomical fit and outcomes, and that personalization will become a structural shift in orthopedics. The commercial process typically requires 6 weeks, or 2 to 3 weeks for expedited cases, while the overall median time is approximately 10 weeks due to surgeon scheduling. The company expects its business mix to be approximately 55% extremities products and 45% hip and knee reconstruction. Personalized products are more complex to manufacture, with an expected gross margin of 73% to 74%, below approximately 78% for large manufacturers, a gap of 4 to 5 percentage points, although lower selling costs may partially offset this difference. The company maintains price parity with conventional implants to reduce resistance to premium pricing. The report also argues that orthopedic robots have historically focused on optimizing the placement of standardized implants but could evolve to execute patient-specific plans. restor3d may benefit from this shift if it can control the implant, planning, and lightweight handheld robot together. Ancora Heart's AccuCinch is intended for patients with heart failure with reduced ejection fraction whose symptoms remain uncontrolled by medication and pacemakers. The system enters the left ventricle through the aortic valve, anchors and tightens an implant to reduce the enlarged left ventricle, lower wall stress, and promote reverse remodeling. It seeks to fill the treatment gap between guideline-directed medical therapy or cardiac resynchronization therapy and left ventricular assist devices or heart transplantation. The pivotal CORCINCH-HF clinical program is a 400-patient, 12-month, multicenter randomized controlled trial comparing AccuCinch plus guideline-directed medical therapy with medical therapy alone. The six-month analysis of the first 250 patients met all endpoints listed in the report, including the 30-day primary safety endpoint, the primary efficacy endpoints of six-minute walk distance and the Kansas City Cardiomyopathy Questionnaire, and the six-month left ventricular end-diastolic volume endpoint. Enrollment of 330 patients has now been completed, while the full cohort's 12-month readout is still pending. Because the device received FDA Breakthrough Device designation, the company plans to submit 5 PMA modules. It has submitted 4, of which 3 have reportedly been reviewed and accepted according to management, potentially allowing part of the regulatory review to proceed before the complete clinical data are available. Route 92 Medical develops catheter systems for thrombectomy in ischemic stroke, including the Monopoint approach, the HiPoint and FreeClimb large-bore aspiration catheters, and the Tenzing delivery catheter. Its objective is to enable more direct, large-bore clot aspiration through tortuous cerebral vessels while simplifying physician workflows. Management believes that the market remains underpenetrated, has favorable reimbursement, and is not yet technologically mature, leaving room for differentiated platforms to gain share. The company has completed the buildout of its U.S. commercial network, with 48 territories and more than 70 commercial personnel. Revenue in 2025 grew by nearly 100%, the annualized revenue run rate is expected to exceed USD 60 million this year, U.S. adoption is approaching 250 accounts, and the company is preparing to begin an initial overseas expansion. Its thesis has progressed from product feasibility to commercial scale, but growth still needs to be validated through account adoption and international expansion. Distalmotion's DEXTER is designed for routine, high-frequency minimally invasive procedures and ambulatory surgery centers. Unlike conventional robots intended for large operating rooms and complex cases, DEXTER is smaller and mobile and can be docked within minutes. Physicians can switch between laparoscopic and robotic operation without redocking, while its open architecture permits the use of preferred visualization systems and advanced instruments. The company's opportunity assessment is based on the migration of procedures from hospitals to lower-cost outpatient settings. DEXTER aims to expand robot-assisted surgery from large academic medical centers to ambulatory surgery centers and integrated healthcare networks through lower costs and greater operational flexibility. Noah Medical's Galaxy is a robotic bronchoscopy system that uses two-dimensional images generated by a compatible C-arm to create three-dimensional reconstructions through digital tomosynthesis. It then overlays the target location onto live X-ray images, allowing physicians to determine whether the tool has entered the lung nodule during biopsy. The system also uses a disposable bronchoscope. Management characterizes first-generation robotic bronchoscopy as having solved the navigation problem, while Galaxy seeks to additionally solve the real-time lesion localization problem, with the objective of improving the reliability and diagnostic yield of lung nodule sampling. Galaxy received FDA approval and was commercially launched in 2023 and remains in the early stages of expansion in the endoluminal robotics market. ISRG's Ion and JNJ's Monarch also participate in this rapidly growing field, so whether real-time imaging and localization translate into adoption and improved diagnostic outcomes is central to validating Galaxy's differentiation. Mercy BioAnalytics' Mercy Halo platform does not rely on the scarce circulating tumor DNA found in blood. Instead, it detects more abundant tumor-associated extracellular vesicles released by living cells and identifies cancer markers co-occurring on the same vesicle to balance sensitivity and specificity. Its first product, Evident, is intended for annual ovarian cancer screening in postmenopausal women. In a blinded analysis of archived samples from a large randomized trial in the United Kingdom, Evident achieved 89% sensitivity and 98% specificity for stage I and stage II ovarian cancer. The company also completed a longitudinal analysis involving 200 ovarian cancer cases, approximately ten times as many controls, and approximately 3,000 samples. Management stated that sensitivity remained stable over multiple years of screening and that the improvement in early detection relative to the original trial's screening tool was statistically significant. The first module of the modular PMA has been accepted, two additional modules are planned for submission this year, and the final clinical validation module is expected to be submitted next year. The other two diagnostics companies are at different stages of commercialization. Cleveland Diagnostics' IsoPSA test examines the structure of the PSA protein rather than only measuring its concentration, aiming to improve the specificity of prostate cancer screening and reduce unnecessary biopsies. Foundational requirements including FDA approval, guideline inclusion, Medicare reimbursement, and reimbursement from some commercial insurers are already in place, shifting the focus to commercial execution. Inflammatix's TriVerity is a rapid blood test for acute care that distinguishes bacterial from viral infections and assesses disease severity to support treatment selection and patient placement. The investment implications section does not assign a unified rating to the ten private companies. Instead, it presents Bernstein's existing views on the public companies under coverage: ABT, BSX, DXCM, ISRG, MDLN, MDT, SYK, PODD, WAT, Agilent, Guardant, and Natera are rated Outperform; EW, JNJ, TNDM, ZBH, Avantor, Illumina, Revvity, and Thermo Fisher are rated Market-Perform. This grouping shows that the report takes a differentiated company-by-company view of the medical technology and life science tools sectors rather than offering a single directional industry call. Target prices and price benchmarks as of August 27, 2026 are presented separately by company and cannot be combined into an overall target price for the report.

Analysis framework

Using conference fireside chats and management statements as its primary materials, the report examines five categories of questions for each company in sequence: what clinical gap the product addresses, how the technology differs from existing solutions, why the target market may expand, how far clinical or regulatory progress has advanced, and what commercial conditions are required for scaled adoption. It then supplements the sector investment context with existing public-company ratings and a target-price table but does not aggregate the ten private company cases into a unified valuation.

Methodology notes

• (Method Outside the Vocabulary)

  Management Fireside Chats and Company Case Review

  Based on management discussions with ten private companies, the report extracts product mechanisms, market positioning, clinical or regulatory progress, and commercialization highlights. This information primarily reflects company statements rather than the results of a unified quantitative model.

• Industry/Sector Analysis FrameworkSupply-demand framework

  Analysis of Unpenetrated Patient Demand and Adoption Pathways

  The report matches unmet demand in areas such as non-insulin-treated diabetes, drug-refractory tremor, Parkinson's disease, heart failure, and stroke intervention with supply-side conditions such as referrals, reimbursement, ease of use, and commercial networks to explain the potential for market expansion.

• Competition and Strategy FrameworkProduct life cycle

  Stage Assessment from Clinical Validation and Regulatory Approval to Commercial Scale-Up

  The report distinguishes among products that have received FDA clearance and been commercially launched, products undergoing pivotal trials or PMA review, and products that already have reimbursement foundations but still need to expand sales, thereby identifying each company's next validation milestone.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Biolinq

  Targets continuous glucose monitoring for people with type 2 diabetes who do not use insulin through the Shine needle-free biowearable sensor.

  Strengths

  FDA De Novo clearance, a shallow intradermal microsensor, phone-independent LED indicators, and a semiconductor manufacturing process.

  Weaknesses

  The appropriate usage frequency, product form, and information presentation for the target population still need to be validated.

  Comparison

  The company believes intermittent use can provide more insight than year-round finger-stick testing and reduces conventional CGM adoption barriers through a needle-free form factor.

  Risks

  Scaling requires maintaining consistency in sensor chemistry, calibration, accuracy, and yield.

• Insightec

  Uses Exablate MR-guided focused ultrasound to treat drug-refractory essential tremor and certain motor symptoms of Parkinson's disease.

  Strengths

  Completely incisionless, typically permits same-day discharge, and Exablate Prime significantly shortens some procedure times.

  Weaknesses

  Patient conversion for the procedure is highly dependent on physician referral networks.

  Comparison

  Focused-ultrasound treatment volume grew 4 times, compared with 1.5 times growth in deep brain stimulation over the same period, primarily expanding the population of patients who previously did not undergo surgery.

  Risks

  It remains to be seen whether the Parkinson's disease market can replicate the referral and adoption pathway established in essential tremor.

• restor3d

  Uses AI planning and 3D printing to provide patient-specific orthopedic implants and surgical plans.

  Strengths

  Controls digital planning, personalized implants, and in-house 3D printing while pursuing price parity with conventional products.

  Weaknesses

  Expected gross margin of 73% to 74% is below approximately 78% for large manufacturers, and process times are also affected by surgeon scheduling.

  Comparison

  Compared with off-the-shelf implants available in a limited range of sizes, the company emphasizes matching each patient's anatomy.

  Risks

  Delivery efficiency, physician adoption, and lower gross margins for personalized solutions require continued validation.

• Ancora Heart

  Uses AccuCinch to reduce an enlarged left ventricle through a transcatheter procedure, filling the gap between medication or pacing therapy and LVAD implantation or heart transplantation.

  Strengths

  The six-month analysis of the first 250 patients met all stated endpoints, and the device has FDA Breakthrough Device designation and a modular PMA pathway.

  Weaknesses

  The product remains in the pivotal clinical and approval stage.

  Comparison

  Positioned after insufficient response to guideline-directed medical therapy and before more invasive advanced heart failure treatments.

  Risks

  The full cohort's 12-month results and the review outcomes for the remaining PMA modules are still pending.

• Route 92 Medical

  Uses large-bore aspiration and the Monopoint catheter approach to improve thrombectomy workflows for ischemic stroke.

  Strengths

  Has established 48 U.S. sales territories, employs more than 70 commercial personnel, and is approaching adoption by 250 U.S. accounts.

  Weaknesses

  Its international commercial infrastructure is still in the launch stage.

  Comparison

  The products emphasize deliverability through tortuous cerebral vessels and simplification of physician workflows.

  Risks

  Revenue growth, account penetration, and international expansion still require sustained execution.

• Distalmotion

  Uses DEXTER to bring robot-assisted surgery to routine, high-frequency minimally invasive procedures and ambulatory surgery centers.

  Strengths

  The system is compact and mobile, can be docked within minutes, permits switching between laparoscopic and robotic operation, and supports an open architecture.

  Weaknesses

  The report does not provide adoption-scale or financial data.

  Comparison

  Compared with conventional robots designed for large operating rooms and complex cases, DEXTER emphasizes flexibility and operational efficiency in outpatient settings.

  Risks

  The opportunity depends on the migration of procedures to lower-cost outpatient settings and actual adoption by outpatient facilities.

• Noah Medical

  Combines Galaxy robotic bronchoscopy with real-time three-dimensional reconstruction and augmented fluoroscopy to support localization during lung nodule biopsy.

  Strengths

  Embedded imaging, real-time confirmation that the tool has entered the lesion, and a disposable bronchoscope; received FDA approval and was commercially launched in 2023.

  Weaknesses

  It remains in the early stages of establishing its presence in the endoluminal robotics market.

  Comparison

  The company states that first-generation systems primarily solved navigation, while Galaxy further addresses real-time localization; ISRG's Ion and JNJ's Monarch are also active in this field.

  Risks

  Whether the imaging differentiation can translate into higher diagnostic yield and commercial adoption still needs to be validated.

• Mercy BioAnalytics

  Uses the Mercy Halo platform and Evident to detect extracellular vesicles for early screening of ovarian and other cancers.

  Strengths

  Reported 89% sensitivity and 98% specificity in early-stage ovarian cancer detection, with longitudinal analysis showing stable sensitivity over multiple years.

  Weaknesses

  Final clinical validation and full regulatory approval have not yet been completed.

  Comparison

  Rather than relying on scarce circulating tumor DNA, the company targets more abundant tumor-associated extracellular vesicles.

  Risks

  Subsequent PMA modules and final clinical validation results remain critical.

• Cleveland Diagnostics

  Uses IsoPSA to assess PSA protein structure, improving the specificity of prostate cancer screening and reducing unnecessary biopsies.

  Strengths

  Already has the commercialization foundations of FDA approval, guideline inclusion, Medicare reimbursement, and reimbursement from some commercial insurers.

  Weaknesses

  The current focus has shifted to commercial execution.

  Comparison

  Unlike tests that only measure PSA concentration, IsoPSA analyzes protein structure.

  Risks

  It remains to be validated whether the regulatory and reimbursement foundations can be converted into market adoption.

• Inflammatix

  Uses the TriVerity rapid blood test to distinguish bacterial from viral infections and assess disease severity.

  Strengths

  Supports pathogen-type determination, severity assessment, treatment selection, and patient placement.

  Weaknesses

  The report does not provide commercial-scale data, clinical data, or a regulatory timeline.

Key data

• Number of Conference Companies10 companiesThe inaugural The Makings of Medtech private company conference
• Exablate Prime Procedure Time1 hour for approximately 40% of recent casesThe first-generation platform typically required approximately 2 hours; some institutions can complete 4 to 5 procedures within 8 to 10 hours
• Growth in Focused-Ultrasound Treatment Volume4 timesDeep brain stimulation treatment volume grew 1.5 times over the same period
• Potential U.S. Parkinson's Disease PatientsApproximately 1 millionInsightec aims to build a corresponding referral network
• Expected restor3d Business MixExtremities 55%, joint reconstruction 45%Extremities include shoulder and ankle; joint reconstruction includes hip and knee
• Expected restor3d Gross Margin73% to 74%Approximately 78% for large manufacturers, a gap of approximately 4 to 5 percentage points
• CORCINCH-HF Design400-patient, 12-month randomized controlled trialThe six-month analysis of the first 250 patients met all stated endpoints, and 330 patients have been enrolled
• AccuCinch PMA Modules5 in total, 4 submitted, of which 3 have been reviewed and acceptedDisclosed by management; the product has FDA Breakthrough Device designation
• Route 92 U.S. Commercial Network48 territories and more than 70 commercial personnelU.S. adoption is approaching 250 accounts
• Route 92 Growth2025 revenue grew by nearly 100%, and this year's annualized revenue run rate is expected to exceed USD 60mnThe company is also preparing to begin an initial overseas expansion
• Galaxy Regulatory Approval and Commercialization Year2023Received FDA approval and was commercially launched
• Evident Early-Stage Ovarian Cancer Detection Performance89% sensitivity and 98% specificityBlinded archived-sample analysis for stage I and stage II ovarian cancer
• Scale of Mercy Longitudinal Analysis200 cases, approximately ten times as many controls, and approximately 3,000 samplesManagement stated that sensitivity remained stable over multiple years
• Public Company Price Benchmark DateAugust 27, 2026Closing-price and target-price benchmark in the report's ticker table

Impact & implications

The report argues that the value of the next stage of medical technology innovation will come not only from the performance of individual devices but also from the combined improvement of technology, clinical workflows, patient behavior, physician referrals, site-of-care economics, and regulatory pathways. Cleared products must demonstrate adoption and scale-up capabilities, while clinical-stage products must complete pivotal readouts and PMA review. Existing public-company ratings also remain clearly differentiated, indicating that Bernstein does not characterize private-company innovation as a uniformly bullish or bearish conclusion for the entire sector.

Risks

• The product form, information display, and intermittent-use frequency that Biolinq's target population will adopt remain uncertain, while scale-up also requires maintaining sensor accuracy and yield.
• Growth in Insightec's procedure volume depends on neurosurgeons and neurologists establishing effective referral networks, and the Parkinson's disease market remains at an early stage.
• restor3d's gross margin for personalized manufacturing is approximately 4 to 5 percentage points below that of large manufacturers, while delivery times are also affected by surgeon scheduling.
• Ancora Heart still needs to obtain the full cohort's 12-month clinical readout and complete the PMA review.
• Noah Medical remains in the early stages of commercial expansion, and whether real-time localization can improve diagnostic outcomes and adoption rates still needs to be validated.
• Mercy BioAnalytics still needs to complete the subsequent PMA modules and final clinical validation.
• Although Cleveland Diagnostics has established multiple market-access prerequisites, it still needs to demonstrate commercial execution capabilities.

What to watch

• Track how people with type 2 diabetes who do not use insulin actually adopt Biolinq's needle-free, intermittently worn Shine.
• Monitor the proportion of 1-hour Exablate Prime cases, daily procedure capacity, and development of the Parkinson's disease referral network.
• Watch the 12-month clinical readout for the full CORCINCH-HF cohort and progress on the remaining AccuCinch PMA modules.
• Track Route 92's annualized revenue run rate above USD 60 million, U.S. account adoption, and initial international expansion.
• Monitor whether Galaxy's real-time localization capabilities translate into higher diagnostic yield and commercial adoption.
• Watch the two PMA modules Mercy plans to submit this year and the final clinical validation module planned for next year.
• Track Cleveland Diagnostics' progress in converting FDA approval, guideline inclusion, and reimbursement foundations into commercial sales.